Evocalcet API

Xi'an Faithful BioTech Co., Ltd: Your Trusted Evocalcet API Manufacturer & Supplier

Xi'an Faithful BioTech Co., Ltd focuses on the export business of Evocalcet API. Over the years, it has accumulated stable upstream raw material channels and provided high-quality products to customers and researchers in more than 20 countries around the world. With the service concept of integrity, efficiency, and professionalism, we create sustainable cooperation value for our customers.

Evocalcet Introduction

Evocalcet API, or evocrates active pharmaceutical ingredient, is a white crystalline powder and belongs to the class of oral active calcium receptor (CaSR) allosteric agonists, small molecule APIs. Evocalcet API is primarily used in the production of oral tablets for hyperparathyroidism secondary to dialysis in chronic kidney disease. It is also suitable for pharmacological research related to endocrine metabolism. This drug effectively inhibits the secretion of parathyroid hormone by allosterically regulating the calcium receptors on the surface of parathyroid cells, enhancing their sensitivity to extracellular calcium ions, without increasing blood calcium concentration. It is a core pharmaceutical raw material for next-generation kidney disease mineral metabolism regulation.

Specifications 

Application area 

Evocalcet API core applications are concentrated in the industrial production of oral nephrology formulations, specifically for preparing tablets to treat secondary hyperparathyroidism in dialysis patients. It stabilizes and lowers parathyroid hormone levels by regulating calcium-sensitive receptors, improving calcium and phosphorus metabolism disorders and alleviating dialysis complications such as renal osteodystrophy and vascular calcification. It is a next-generation clinical pharmaceutical raw material that can replace traditional cinacalcet. Simultaneously, it is supplied in large quantities to pharmaceutical R&D companies for formulation process optimization, formulation stability studies, and human pharmacokinetic trials.​​​​​​​

Main Advantages of Evocalcet

• Second-generation calcimimetic agent with superior safety: Compared to the first-generation drug cinacalcet, Evocalcet API demonstrated non-inferiority in Phase III clinical trials while significantly reducing gastrointestinal adverse reactions.
• Improved oral activity and bioavailability: As an orally effective small molecule drug, its bioavailability is significantly improved compared to the previous generation. Once-daily dosing ensures high patient compliance.
• Precise mechanism of action: As a CaSR allosteric agonist, it precisely regulates PTH secretion, avoiding the risk of elevated serum calcium and phosphorus levels that may be associated with active vitamin D drugs.
• High purity and controllable impurities: Academic research has systematically identified process-related impurities and established mature HPLC detection methods. Our product achieves a purity of over 98%, meeting the stringent impurity control requirements of ICH guidelines.

Contact us allen@faithfulbio.com or Whats App：+86 13137770562

Why choose us

• Guardian of Quality

Always adhere to quality first, integrate resources, and cooperate deeply with compliant large factories to ensure excellent product quality.

• A practitioner of integrity

Our motto is' small trust, big trust '. We operate with integrity and actively solve quality issues, customs problems, and other issues related to tea farmers. We will not only solve problems but also take responsibility.

Quality Control

R&D Results

Packaging and Transportation

After-Sales Service

Qualification Certification

Exhibition

FAQ

Q1: As a second-generation calcimimetic agent, what are the core advantages of Evocalcet compared to cinacalcet?

A1: The core advantage lies in its superior gastrointestinal tolerability. Phase III clinical trials have confirmed that, while maintaining non-inferiority to cinacalcet in efficacy, Evocalcet caused a significantly lower incidence of gastrointestinal adverse reactions.

Q2: Will Evocalcet lead to insufficient efficacy or a higher incidence of gastrointestinal side effects?

A2: Evocalcet has strong target selectivity, weak off-target enzyme inhibition, and high bioavailability of the raw material itself.

Q3: What is the solubility of the Evocalcet API?

A3: The solubility in DMF and DMSO is approximately 5 mg/mL, and in a DMSO:PBS (1:2) system, it is approximately 0.3 mg/mL.

Contact US

Are you  looking  for Evocalcet API？Contact us allen@faithfulbio.com or Whats App：+86 13137770562 to get more information .